New research reveals ADHD isn't one-size-fits-all — covering social media's specific role, why medication rarely 'stops ...

The Food and Drug Administration (FDA) approved a new "first-in-class" medication to help manage attention deficit ...

Experts are calling for changes to ADHD care as new research raises questions about medication safety.

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older ...

Military veterans with PTSD and other mental health conditions may soon be able to use psychedelic drugs to aid in their ...

Groundbreaking research found that behavioral therapy – when used first – was less expensive and more effective than medication in treating children with ADHD.

The FDA has approved Simtriyo (centanafadine) as the first norepinephrine, dopamine, serotonin reuptake inhibitor for adult and pediatric ADHD.

If social media is to be believed, ADHD can be managed with supplements, breathing exercises, herbal remedies, and just about ...

Discover why ADHD often goes undiagnosed in older adults and how recognition can transform their quality of life.

For decades, ADHD was viewed as a childhood condition that mostly affected boys. Researchers now know ADHD manifests ...

A head-to-head trial of ADHD treatments finds dexamphetamine and methylphenidate equally effective, with notable differences ...

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.